kras tcr-transduced pbl
Cell therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 16, 2024 (NCT06253520)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Cholangiocarcinoma · Phase 2
- Colorectal Neoplasms · Phase 2
- Duodenal Neoplasms · Phase 2
- Gastrointestinal Neoplasms · Phase 2
- Liver Neoplasms · Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 2
- Urogenital Neoplasms · Phase 1
Mechanism of action
- GTPase KRasImmunity, passive
KRAS immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06690281 | Phase 2 | Jan 1, 2025 | National Cancer Institute (NCI) |
| NCT06253520 | Phase 1 | May 16, 2024 | National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 2 | 2 | 2024 |
1 organizations
Page 1 / 1